{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T19:42:45Z","timestamp":1770493365343,"version":"3.49.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"29","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.vaccine.2021.05.077","type":"journal-article","created":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T09:08:18Z","timestamp":1622624898000},"page":"3862-3870","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Single-dose combination nanovaccine induces both rapid and durable humoral immunity and toxin neutralizing antibody responses against Bacillus anthracis"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5833-7456","authenticated-orcid":false,"given":"Sean M.","family":"Kelly","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina R.","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2012-7880","authenticated-orcid":false,"given":"Ross","family":"Darling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew C.","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan H.","family":"Bellaire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Wannemuehler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7955-5353","authenticated-orcid":false,"given":"Balaji","family":"Narasimhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.vaccine.2021.05.077_b0005","first-page":"295","article-title":"The ecology of anthrax spores: tough but not invincible","volume":"36","author":"Dragon","year":"1995","journal-title":"Can Vet J = La Rev Vet Can"},{"key":"10.1016\/j.vaccine.2021.05.077_b0010","article-title":"Anthrax in humans and animals","volume":"219","author":"WHO","year":"2008","journal-title":"World Organ Anim Heal"},{"issue":"8","key":"10.1016\/j.vaccine.2021.05.077_b0015","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1586\/14760584.2013.814860","article-title":"Anthrax vaccines: present status and future prospects","volume":"12","author":"Kaur","year":"2013","journal-title":"Expert Rev Vaccines"},{"issue":"10","key":"10.1016\/j.vaccine.2021.05.077_b0020","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3201\/eid0810.020349","article-title":"Antimicrobial postexposure prophylaxis for anthrax: adverse events and adherence","volume":"8","author":"Shepard","year":"2002","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2021.05.077_b0025","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1146\/annurev-micro-091014-104523","article-title":"Anthrax pathogenesis","volume":"69","author":"Moayeri","year":"2015","journal-title":"Annu Rev Microbiol"},{"issue":"3\u20134","key":"10.1016\/j.vaccine.2021.05.077_b0030","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.vaccine.2003.07.004","article-title":"Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine","volume":"22","author":"Little","year":"2004","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2021.05.077_b0035","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.phrp.2012.07.006","article-title":"Serological correlate of protection in guinea pigs for a recombinant protective antigen anthrax vaccine produced from Bacillus Brevis","volume":"3","author":"Chun","year":"2012","journal-title":"Osong Public Heal Res Perspect"},{"issue":"1","key":"10.1016\/j.vaccine.2021.05.077_b0040","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1365-2249.2012.04637.x","article-title":"Bacillus-derived poly-\u03b3-glutamic acid reciprocally regulates the differentiation of T helper 17 and regulatory T cells and attenuates experimental autoimmune encephalomyelitis","volume":"170","author":"Lee","year":"2012","journal-title":"Clin Exp Immunol"},{"issue":"151","key":"10.1016\/j.vaccine.2021.05.077_b0045","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1126\/scitranslmed.3004073","article-title":"Anthrax vaccine induced antibodies provide cross-species prediction of survival to aerosol challenge","volume":"4","author":"Fay","year":"2012","journal-title":"Sci Transl Med"},{"issue":"51","key":"10.1016\/j.vaccine.2021.05.077_b0050","doi-asserted-by":"crossref","first-page":"6512","DOI":"10.1016\/j.vaccine.2016.06.041","article-title":"Cross-species prediction of human survival probabilities for accelerated anthrax vaccine absorbed (AVA) regimens and the potential for vaccine and antibiotic dose sparing HHS public access","volume":"34","author":"Stark","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.05.077_b0055","doi-asserted-by":"crossref","unstructured":"Kondakova OA, Nikitin NA, Evtushenko EA, Ryabchevskaya EM, Atabekov JG, Karpova OV. Expert review of vaccines vaccines against anthrax based on recombinant protective antigen: problems and solutions vaccines against anthrax based on recombinant protective antigen: problems and solutions; 2019. https:\/\/doi.org\/10.1080\/14760584.2019.1643242.","DOI":"10.1080\/14760584.2019.1643242"},{"key":"10.1016\/j.vaccine.2021.05.077_b0060","doi-asserted-by":"crossref","unstructured":"Nicholson A, Wollek S, Kahn B, Herrmann J. In: Nicholson A, Wollek S, Kahn B, Herrmann J, editors. The Nation\u2019s Medical Countermeasure Stockpile. Washington, D.C.: National Academies Press; 2016. https:\/\/doi.org\/10.17226\/23532.","DOI":"10.17226\/23532"},{"issue":"3","key":"10.1016\/j.vaccine.2021.05.077_b0065","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1039\/C8BM01443D","article-title":"Single dose combination nanovaccine provides protection against influenza A virus in young and aged mice","volume":"7","author":"Ross","year":"2019","journal-title":"Biomater Sci"},{"issue":"1","key":"10.1016\/j.vaccine.2021.05.077_b0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-21292-2","article-title":"Efficacy of mucosal polyanhydride nanovaccine against respiratory syncytial virus infection in the neonatal calf","volume":"8","author":"McGill","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2021.05.077_b0075","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.actbio.2019.10.016","article-title":"Single-dose combination nanovaccine induces both rapid and long-lived protection against pneumonic plague","volume":"100","author":"Wagner","year":"2019","journal-title":"Acta Biomater"},{"issue":"2","key":"10.1016\/j.vaccine.2021.05.077_b0080","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/adhm.201200181","article-title":"Evaluation of biocompatibility and administration site reactogenicity of polyanhydride-particle-based platform for vaccine delivery","volume":"2","author":"Huntimer","year":"2013","journal-title":"Adv Healthc Mater"},{"issue":"1","key":"10.1016\/j.vaccine.2021.05.077_b0085","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/jbm.a.30510","article-title":"Synthesis and characterization of novel polyanhydrides with tailored erosion mechanisms","volume":"76","author":"Torres","year":"2006","journal-title":"J Biomed Mater Res - Part A"},{"issue":"1","key":"10.1016\/j.vaccine.2021.05.077_b0090","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/jbm.b.32820","article-title":"Single immunization with a suboptimal antigen dose encapsulated into polyanhydride microparticles promotes high titer and avid antibody responses","volume":"101","author":"Huntimer","year":"2013","journal-title":"J Biomed Mater Res B Appl Biomater"},{"key":"10.1016\/j.vaccine.2021.05.077_b0095","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00325","article-title":"Room temperature stable PspA-based nanovaccine induces protective immunity","volume":"9","author":"Wagner-Mu\u00f1iz","year":"2018","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2021.05.077_b0100","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1021\/mp2004059","article-title":"Amphiphilic polyanhydride nanoparticles stabilize Bacillus anthracis protective antigen","volume":"9","author":"Petersen","year":"2012","journal-title":"Mol Pharm"},{"issue":"5","key":"10.1016\/j.vaccine.2021.05.077_b0105","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nrmicro.2016.190","article-title":"Cyclic Di-GMP: second messenger extraordinaire","volume":"15","author":"Jenal","year":"2017","journal-title":"Nat Rev Microbiol"},{"issue":"5","key":"10.1016\/j.vaccine.2021.05.077_b0110","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.cell.2013.08.014","article-title":"Cyclic dinucleotides and the innate immune response","volume":"154","author":"Danilchanka","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2021.05.077_b0115","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.vaccine.2006.10.033","article-title":"The bacterial second messenger cyclic DiGMP exhibits potent adjuvant properties","volume":"25","author":"Ebensen","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.05.077_b0120","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1016\/j.vaccine.2009.04.053","article-title":"C-Di-GMP as a vaccine adjuvant enhances protection against systemic methicillin-resistant Staphylococcus aureus (MRSA) infection","volume":"27","author":"Hu","year":"2009","journal-title":"Vaccine"},{"issue":"20","key":"10.1016\/j.vaccine.2021.05.077_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2019.04.004","article-title":"STING pathway stimulation results in a differentially activated innate immune phenotype associated with low nitric oxide and enhanced antibody titers in young and aged mice","volume":"37","author":"Darling","year":"2019","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2021.05.077_b0130","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/jbm.a.30545","article-title":"Single dose vaccine based on biodegradable polyanhydride microspheres can modulate immune response mechanism","volume":"76","author":"Kipper","year":"2006","journal-title":"J Biomed Mater Res - Part A"},{"key":"10.1016\/j.vaccine.2021.05.077_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.actbio.2019.10.016","article-title":"Single-dose combination nanovaccine induces both rapid and long-lived protection against pneumonic plague","volume":"100","author":"Wagner","year":"2019","journal-title":"Acta Biomater"},{"issue":"6","key":"10.1016\/j.vaccine.2021.05.077_b0140","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1128\/CVI.00513-09","article-title":"Comparison of three anthrax toxin neutralization assays","volume":"17","author":"Ngundi","year":"2010","journal-title":"Clin Vaccine Immunol"},{"issue":"43","key":"10.1016\/j.vaccine.2021.05.077_b0145","doi-asserted-by":"crossref","first-page":"6379","DOI":"10.1016\/j.vaccine.2018.09.012","article-title":"Improving the stability of recombinant anthrax protective antigen vaccine","volume":"36","author":"Verma","year":"2018","journal-title":"Vaccine"},{"issue":"20","key":"10.1016\/j.vaccine.2021.05.077_b0150","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1016\/j.vaccine.2015.03.037","article-title":"Anthrax vaccine recipients lack antibody against the loop neutralizing determinant: a protective neutralizing epitope from Bacillus anthracis protective antigen","volume":"33","author":"Oscherwitz","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.05.077_b0155","doi-asserted-by":"crossref","unstructured":"Artenstein AW. Bioterrorism and biodefense. In: Infectious diseases, vol. 1. Elsevier; 2017. p. 670\u2013679.e1. https:\/\/doi.org\/10.1016\/B978-0-7020-6285-8.00075-7.","DOI":"10.1016\/B978-0-7020-6285-8.00075-7"},{"issue":"4","key":"10.1016\/j.vaccine.2021.05.077_b0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6804a1","article-title":"Use of Anthrax Vaccine in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2019","volume":"68","author":"Bower","year":"2019","journal-title":"MMWR Recomm Reports"},{"issue":"36","key":"10.1016\/j.vaccine.2021.05.077_b0165","doi-asserted-by":"crossref","first-page":"4676","DOI":"10.1016\/j.vaccine.2008.06.099","article-title":"C-Di-GMP is an effective immunomodulator and vaccine adjuvant against pneumococcal infection","volume":"26","author":"Ogunniyi","year":"2008","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2021.05.077_b0170","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S1074-7613(03)00171-7","article-title":"TNF\/INOS-producing dendritic cells mediate innate immune defense against bacterial infection","volume":"19","author":"Serbina","year":"2003","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.vaccine.2021.05.077_b0175","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aah6789","article-title":"Inflammatory monocytes hinder antiviral B cell responses","volume":"1","author":"Sammicheli","year":"2016","journal-title":"Sci Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2021.05.077_b0180","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.4049\/jimmunol.1300263","article-title":"BAFF- and APRIL-dependent maintenance of antibody titers after immunization with T-dependent antigen and CD1d-binding ligand","volume":"191","author":"Shah","year":"2013","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2021.05.077_b0185","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.4049\/jimmunol.1303158","article-title":"Nitric oxide regulates BAFF expression and T cell-independent antibody responses","volume":"193","author":"Giordano","year":"2014","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2021.05.077_b0190","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1073\/pnas.1117710109","article-title":"Nitric Oxide (NO) side of lymphatic flow and immune surveillance","volume":"109","author":"Schmid-Schonbein","year":"2012","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"10.1016\/j.vaccine.2021.05.077_b0195","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41541-018-0089-x","article-title":"Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want","volume":"3","author":"HogenEsch","year":"2018","journal-title":"npj Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2021.05.077_b0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/emi.2016.40","article-title":"Alum: an old dog with new tricks","volume":"5","author":"Wen","year":"2016","journal-title":"Emerg Microbes Infect"},{"issue":"4","key":"10.1016\/j.vaccine.2021.05.077_b0205","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/ni.2237","article-title":"Regulation of inflammasome signaling","volume":"13","author":"Rathinam","year":"2012","journal-title":"Nat Immunol"},{"issue":"27","key":"10.1016\/j.vaccine.2021.05.077_b0210","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1016\/j.vaccine.2016.04.081","article-title":"Toward understanding the mechanism underlying the strong adjuvant activity of aluminum salt nanoparticles","volume":"34","author":"Ruwona","year":"2016","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2021.05.077_b0215","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.vaccine.2015.11.025","article-title":"Neutralizing antibody and functional mapping of Bacillus anthracis protective antigen\u2014the first step toward a rationally designed anthrax vaccine","volume":"34","author":"McComb","year":"2016","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2021.05.077_b0220","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1128\/iai.56.7.1807-1813.1988","article-title":"Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis toxin","volume":"56","author":"Little","year":"1988","journal-title":"Infect Immun"},{"issue":"3","key":"10.1016\/j.vaccine.2021.05.077_b0225","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1099\/13500872-142-3-707","article-title":"Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal antibodies","volume":"142","author":"Little","year":"1996","journal-title":"Microbiology"},{"issue":"6","key":"10.1016\/j.vaccine.2021.05.077_b0230","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nbt0602-597","article-title":"Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity","volume":"20","author":"Maynard","year":"2002","journal-title":"Nat Biotechnol"},{"issue":"25","key":"10.1016\/j.vaccine.2021.05.077_b0235","doi-asserted-by":"crossref","first-page":"9193","DOI":"10.1073\/pnas.0400187101","article-title":"Anchored periplasmic expression, a versatile technology for the isolation of high-affinity antibodies from Escherichia coli-expressed libraries","volume":"101","author":"Harvey","year":"2004","journal-title":"Proc Natl Acad Sci"},{"issue":"37","key":"10.1016\/j.vaccine.2021.05.077_b0240","doi-asserted-by":"crossref","first-page":"25077","DOI":"10.1074\/jbc.M109.022061","article-title":"Identification of linear epitopes in Bacillus anthracis protective antigen bound by neutralizing antibodies","volume":"284","author":"Abboud","year":"2009","journal-title":"J Biol Chem"},{"issue":"11","key":"10.1016\/j.vaccine.2021.05.077_b0245","doi-asserted-by":"crossref","first-page":"4859","DOI":"10.1128\/IAI.00117-09","article-title":"Neutralizing monoclonal antibodies directed against defined linear epitopes on domain 4 of anthrax protective antigen","volume":"77","author":"Kelly-Cirino","year":"2009","journal-title":"Infect Immun"},{"issue":"Nov","key":"10.1016\/j.vaccine.2021.05.077_b0250","first-page":"1","article-title":"Long-lived plasma cells in mice and men","volume":"9","author":"Brynjolfsson","year":"2018","journal-title":"Front Immunol"},{"issue":"May","key":"10.1016\/j.vaccine.2021.05.077_b0255","first-page":"1","article-title":"Survival of long-lived plasma cells (LLPC): piecing together the puzzle","volume":"10","author":"Lightman","year":"2019","journal-title":"Front Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21006721?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21006721?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:58:36Z","timestamp":1759402716000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21006721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":51,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0264410X21006721"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.05.077","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Single-dose combination nanovaccine induces both rapid and durable humoral immunity and toxin neutralizing antibody responses against Bacillus anthracis","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.05.077","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}